antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2022-67-9-10-79-89antibiotics-971Research ArticleОБЗОРЫREVIEWSПневмоцистная пневмония при ревматических заболеваниях: вопросы профилактикиPneumocystis Pneumonia in Rheumatic Diseases: Prevention Issueshttps://orcid.org/0000-0002-0928-3911ГридневаГ. И.GridnevaG. I.

Гриднева Галина Игоревна — к. м. н., научный сотрудник лаборатории коморбидных инфекций и вакцинопрофилактики

ResearcherID: AFN-9929-2022

eLIBRARY SPIN-код: 2849-5029

Scopus Author ID: 56381565500 

Каширское шоссе, 34А, г. Москва, 115522

Galina I. Gridneva — Ph. D. in Medicine, Researcher at the Laboratory of Comorbid Infections and Vaccine Prevention

ResearcherID: AFN-9929-2022

eLIBRARY SPIN: 2849-5029

Scopus Author ID: 56381565500 

34A Kashirskoe highway, Moscow 

gigridneva@mail.ruhttps://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

Белов Борис Сергеевич — д. м. н., заведующий лабораторией коморбидных инфекций и вакцинопрофилактики

Researcher ID: ABD-2219-2020

eLIBRARY SPIN-код: 3298-4315

Scopus Author ID: 7004592537 

Москва

Boris S. Belov — D. Sc. in Medicine, Head of the Laboratory of Comorbid Infections and Vaccine Prevention

Researcher ID: ABD-2219-2020

eLIBRARY SPIN: 3298-4315

Scopus Author ID: 7004592537 

Moscow

https://orcid.org/0000-0002-1833-5357АроноваЕ. С.AronovaE. S.

Аронова Евгения Сергеевна — к. м. н., научный сотрудник лаборатории коморбидных инфекций и вакцинопрофилактики

Researher ID AAD-1849-2019

eLIBRARY SPIN-код: 8993-5795

Scopus Author ID 55913403200 

Москва

Evgenia S. Aronova — Ph. D. in Medicine, Researcher at the Laboratory of Comorbid Infections and Vaccine Prevention

Researcher ID: AAD-1849-2019

eLIBRARY SPIN: 8993-5795

Scopus Author ID: 55913403200 

Moscow

ФГБНУ «Научно-исследовательский институт ревматологии им. В. А. Насоновой»РоссияV. A. Nasonova Research Injstitute of RheumatologyRussian Federation202229122022679-107989Copyright © Гриднева Г.И., Белов Б.С., Аронова Е.С., 20222022Гриднева Г.И., Белов Б.С., Аронова Е.С.Gridneva G.I., Belov B.S., Aronova E.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/971

Частота случаев выявления пневмоцистной пневмонии (ППн) у пациентов с ревматическими заболеваниями (РЗ) продолжает нарастать. Этому способствует, помимо применения цитостатиков и глюкокортикоидов (ГК), всё более широкое применение генно-инженерных биологических препаратов (ГИБП). Летальность при ППн среди больных РЗ чрезвычайно высока, поэтому вопросы её профилактики стоят как нельзя остро. В работах европейских и американских учёных основное внимание уделяется частоте выявления ППн и определению удельного «веса» тех или иных факторов риска, а рекомендации по профилактике сформулированы с определенной сдержанностью. Представители азиатских врачебных сообществ единодушны в отношении необходимости профилактики ППн, обсуждается лишь дозировка лекарственных препаратов и продолжительность курса лечения.

The incidence of pneumocystis pneumonia (PCP) in patients with rheumatic diseases (RD) continues to increase. This is facilitated by the increasing use of genetically engineered biological agents in addition to the use of cytostatics and glucocorticoids. Mortality due to PCP among patients with RD is extremely high, so the issues of its prevention are relevant. European and American scientists focus on the frequency of detection of PCP and the determination of the proportionality of certain risk factors, while the recommendations for prevention are formulated cautiously. Asian medical communities are unanimous in their opinion about the need to prevent PCP, only the dosage of drugs and the duration of the course of treatment are discussed.

пневмоцистная инфекцияпневмонияпрофилактикаревматические заболеванияpneumocystis infectionpneumoniapreventionrheumatic diseasesСтатья подготовлена в рамках научно-исследовательских работ ФГБНУ «Научно-исследовательский институт ревматологии им. В. А. Насоновой». № государственного задания 1021051503137-7. Исследование не имело спонсорской поддержки.ReferencesКаражас Н.В., Рыбалкина Т.Н., Корниенко М.Н., Юдицкий М.В. Пневмоцистоз — актуальная иммунодефицит-ассоциированная инфекция: Методические рекомендации. М.: 2009; 75. [Karazhas N.V., Rybalkina T.N., Kornienko M.N., Jyuditskij M.V. Pnevmotsistoz — aktual'naya immunodefitsit-assotsiirovannaya infektsiya: Metodicheskie reko-mendatsii. Moscow: 2009; 75. (in Russian)]Каражас Н.В., Рыбалкина Т.Н., Корниенко М.Н., Юдицкий М.В. Пневмоцистоз — актуальная иммунодефицит-ассоциированная инфекция: Методические рекомендации. М.: 2009; 75. [Karazhas N.V., Rybalkina T.N., Kornienko M.N., Jyuditskij M.V. Pnevmotsistoz — aktual'naya immunodefitsit-assotsiirovannaya infektsiya: Metodicheskie reko-mendatsii. Moscow: 2009; 75. (in Russian)]Furukawa H., Oka S., Shimada K. et al. Serum metabolomic profiles of rheumatoid arthritis patients with acute-onset diffuse interstitial lung disease. Biomark Insights. 2019 Aug 22; 14: 1177271919870472. doi: 10.1177/1177271919870472. eCollection 2019.Furukawa H., Oka S., Shimada K. et al. Serum metabolomic profiles of rheumatoid arthritis patients with acute-onset diffuse interstitial lung disease. Biomark Insights. 2019 Aug 22; 14: 1177271919870472. doi: 10.1177/1177271919870472. eCollection 2019.Kovacs J.A., Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009 Jun 24; 301 (24): 2578–2585. doi: 10.1001/jama.2009.880.Kovacs J.A., Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009 Jun 24; 301 (24): 2578–2585. doi: 10.1001/jama.2009.880.Menon A.A., Berg D.D., Brea E.J. et al. A сase of COVID-19 and зneumocystis jirovecii coinfection. Am J Respir Crit Care Med. 2020 Jul 1; 202 (1): 136–138. doi: 10.1164/rccm.202003-0766LE.Menon A.A., Berg D.D., Brea E.J. et al. A сase of COVID-19 and зneumocystis jirovecii coinfection. Am J Respir Crit Care Med. 2020 Jul 1; 202 (1): 136–138. doi: 10.1164/rccm.202003-0766LE.Белов Б.С., Тарасова Г.М., Буханова Д.С. Профилактика пневмоцистной пневмонии у пациентов с ревматическими заболеваниями: проблемы и поиск решений. Антибиотики и химиотер. 2019; 64 (5–6): 77–89. https://doi.org/10.24411/0235-2990-2019-10035. [Belov B. S., Tarasova G. M., Bukhanova D. S. Prevention of pneumocystic pneumonia in patients with rheumatic diseases: problems and solutions. Antibiotiki i Khimioter = Antibiotics and Chemotherapy. 2019; 64 (5–6): 77–89. https://doi.org/10.24411/0235-2990-2019-10035.Белов Б.С., Тарасова Г.М., Буханова Д.С. Профилактика пневмоцистной пневмонии у пациентов с ревматическими заболеваниями: проблемы и поиск решений. Антибиотики и химиотер. 2019; 64 (5–6): 77–89. https://doi.org/10.24411/0235-2990-2019-10035. [Belov B. S., Tarasova G. M., Bukhanova D. S. Prevention of pneumocystic pneumonia in patients with rheumatic diseases: problems and solutions. Antibiotiki i Khimioter = Antibiotics and Chemotherapy. 2019; 64 (5–6): 77–89. https://doi.org/10.24411/0235-2990-2019-10035.Ward M.M., Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum, 1999, 42(4): 780–789. doi: 10.1002/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M.Ward M.M., Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum, 1999, 42(4): 780–789. doi: 10.1002/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M.Green H., Paul M., Vidal L., Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007; 82 (9): 1052–1059. doi: 10.4065/82.9.1052.Green H., Paul M., Vidal L., Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007; 82 (9): 1052–1059. doi: 10.4065/82.9.1052.Shoji K., Michihata N., Miyairi I. et al. Recent epidemiology of Pneumocystis pneumonia in Japan. J Infect Chemother. 2020 Dec; 26 (12): 1260–1264. doi: 10.1016/j.jiac.2020.07.006. Epub 2020 Aug 1.Shoji K., Michihata N., Miyairi I. et al. Recent epidemiology of Pneumocystis pneumonia in Japan. J Infect Chemother. 2020 Dec; 26 (12): 1260–1264. doi: 10.1016/j.jiac.2020.07.006. Epub 2020 Aug 1.Maini R., Henderson K.L., Sheridan E.A. et al. Increasing Pneumocystis Pneumonia, England, UK, 2000–2010. Emerg Infect Dis. 2013; 19 (3): 386–392. doi: 10.3201/eid1903.121151.Maini R., Henderson K.L., Sheridan E.A. et al. Increasing Pneumocystis Pneumonia, England, UK, 2000–2010. Emerg Infect Dis. 2013; 19 (3): 386–392. doi: 10.3201/eid1903.121151.Shi Y., Du B., Zhao J.L. et al. Etiologies and outcomes of rheumatology patients with acute respiratory failure requiring intensive care: a singlecenter medical records review study of 259 patients. Clin Rheumatol. 2020 Nov; 39 (11): 3479–3488. doi: 10.1007/s10067-020-05080-w. Epub 2020 May 6.Shi Y., Du B., Zhao J.L. et al. Etiologies and outcomes of rheumatology patients with acute respiratory failure requiring intensive care: a singlecenter medical records review study of 259 patients. Clin Rheumatol. 2020 Nov; 39 (11): 3479–3488. doi: 10.1007/s10067-020-05080-w. Epub 2020 May 6.Escudero Siosi A., Andersson M., Woodrow C., Dubey S. AB1074 fatal but preventable — single centre series of 6 cases of pneumocystis jirovecii pneumonia (PJP) in patients with auto-immune inflammatory rheumatic disease (AIIRD) in one year. Annals of the Rheumatic Diseases. 2022; 81: 1657. https://doi.org/10.1136/annrheumdis-2022-eular.2500Escudero Siosi A., Andersson M., Woodrow C., Dubey S. AB1074 fatal but preventable — single centre series of 6 cases of pneumocystis jirovecii pneumonia (PJP) in patients with auto-immune inflammatory rheumatic disease (AIIRD) in one year. Annals of the Rheumatic Diseases. 2022; 81: 1657. https://doi.org/10.1136/annrheumdis-2022-eular.2500Mansharamani N.G., Balachandran D., Vernovsky I. et al. Peripheral blood CD4 + T-lymphocyte counts during pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest. 2000; 118 (3): 712–720. doi: 10.1378/chest.118.3.712.Mansharamani N.G., Balachandran D., Vernovsky I. et al. Peripheral blood CD4 + T-lymphocyte counts during pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest. 2000; 118 (3): 712–720. doi: 10.1378/chest.118.3.712.Ogawa J., Harigai M., Nagasaka K. et al. Prediction of and prophylaxis against pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol. 2005; 15 (2): 91–96. doi: 10.1007/pl00021707.Ogawa J., Harigai M., Nagasaka K. et al. Prediction of and prophylaxis against pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol. 2005; 15 (2): 91–96. doi: 10.1007/pl00021707.Chew L.C., Maceda-Galang L.M., Tan Y.K. et al. Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid. J Clin Rheumatol. 2015 Mar; 21 (2): 72–75. doi: 10.1097/RHU.0000000000000215.Chew L.C., Maceda-Galang L.M., Tan Y.K. et al. Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid. J Clin Rheumatol. 2015 Mar; 21 (2): 72–75. doi: 10.1097/RHU.0000000000000215.Yale S.H., Limper A.H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc. 1996; 71 (1): 5–13. doi: 10.4065/71.1.5.Yale S.H., Limper A.H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc. 1996; 71 (1): 5–13. doi: 10.4065/71.1.5.Li J., Huang X.M., Fang W.G., Zeng X.J. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol. 2006; 12 (3): 114–117. doi: 10.1097/01.rhu.0000221794.24431.36.Li J., Huang X.M., Fang W.G., Zeng X.J. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol. 2006; 12 (3): 114–117. doi: 10.1097/01.rhu.0000221794.24431.36.Stamp L.K., Hurst M. Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol. 2010; 37 (4): 686–688. doi: 10.3899/jrheum.091426.Stamp L.K., Hurst M. Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol. 2010; 37 (4): 686–688. doi: 10.3899/jrheum.091426.Gupta D., Zachariah A., Roppelt H. et al. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature. J Clin Rheumatol. 2008; 14 (5): 267–72. doi: 10.1097/RHU.0b013e31817a7e30.Gupta D., Zachariah A., Roppelt H. et al. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature. J Clin Rheumatol. 2008; 14 (5): 267–72. doi: 10.1097/RHU.0b013e31817a7e30.Demoruelle M.K., Kahr A., Verilhac K. et al. Recent-onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care Res (Hoboken). 2013; 65 (2): 314–323. doi: 10.1002/acr.21857.Demoruelle M.K., Kahr A., Verilhac K. et al. Recent-onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care Res (Hoboken). 2013; 65 (2): 314–323. doi: 10.1002/acr.21857.Mori S., Sugimoto M. Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients: risks and prophylaxis recommendations. Clin Med Insights Circ Respir Pulm Med. 2015 Sep 6; 9 (Suppl 1): 29–40. doi: 10.4137/CCRPM.S23286. eCollection 2015.Mori S., Sugimoto M. Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients: risks and prophylaxis recommendations. Clin Med Insights Circ Respir Pulm Med. 2015 Sep 6; 9 (Suppl 1): 29–40. doi: 10.4137/CCRPM.S23286. eCollection 2015.Kameda H., Fujii T., Nakajima A. et al. Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis. Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2019; 29 (1): 31–40. doi: 10.1080/14397595.2018.1472358. Epub 2018 May 24.Kameda H., Fujii T., Nakajima A. et al. Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis. Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2019; 29 (1): 31–40. doi: 10.1080/14397595.2018.1472358. Epub 2018 May 24.Fragoulis G.E., Dey M., Zhao S.S. on behalf of EULAR Task Force for the screening and prophylaxis of chronic and opportunistic infections in Autoimmune Rheumatic Diseases et al. POS1179 Systematic literature review on the screening and prophylaxis of chronic and opportunistic infections Ann Rheum Dis. 2022; 81: 917–918. doi: 10.1136/ard-2022-223335. Online ahead of print.Fragoulis G.E., Dey M., Zhao S.S. on behalf of EULAR Task Force for the screening and prophylaxis of chronic and opportunistic infections in Autoimmune Rheumatic Diseases et al. POS1179 Systematic literature review on the screening and prophylaxis of chronic and opportunistic infections Ann Rheum Dis. 2022; 81: 917–918. doi: 10.1136/ard-2022-223335. Online ahead of print.Tadros S., Teichtahl A.J., Ciciriello S., Wicks I.P. Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: a case-control study. Semin Arthritis Rheum. 2017; 46 (6): 804–809. doi: 10.1016/j.semarthrit.2016.09.009. Epub 2016 Sep 28.Tadros S., Teichtahl A.J., Ciciriello S., Wicks I.P. Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: a case-control study. Semin Arthritis Rheum. 2017; 46 (6): 804–809. doi: 10.1016/j.semarthrit.2016.09.009. Epub 2016 Sep 28.Demoruelle M.K., Kahr A., Verilhac K. et al. Recent-onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care Res (Hoboken) 2013; 65 (2): 314–323. doi: 10.1002/acr.21857.Demoruelle M.K., Kahr A., Verilhac K. et al. Recent-onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care Res (Hoboken) 2013; 65 (2): 314–323. doi: 10.1002/acr.21857.Park J.W., Curtis J.R., Moon J. et al. Prophylactic effect of trimethoprimsulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018; 77 (5): 644–649. doi: 10.1136/annrheumdis-2017-211796. Epub 2017 Nov 1.Park J.W., Curtis J.R., Moon J. et al. Prophylactic effect of trimethoprimsulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018; 77 (5): 644–649. doi: 10.1136/annrheumdis-2017-211796. Epub 2017 Nov 1.Herrou J., De Lastours V. Predictive factors of pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018; 79 (2): e23. doi: 10.1136/annrheumdis-2018-214718. Epub 2018 Nov 28.Herrou J., De Lastours V. Predictive factors of pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018; 79 (2): e23. doi: 10.1136/annrheumdis-2018-214718. Epub 2018 Nov 28.Park J.W., Curtis J.R., Kim M.J. et al. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroidsclinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole. Arthritis Res Ther. 2019; 21 (1): 207. doi: 10.1136/annrheumdis-2018-214718. Epub 2018 Nov 28.Park J.W., Curtis J.R., Kim M.J. et al. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroidsclinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole. Arthritis Res Ther. 2019; 21 (1): 207. doi: 10.1136/annrheumdis-2018-214718. Epub 2018 Nov 28.Chan S.C.W., Chung H.Y., Lau C.S., Li P.H. Epidemiology, mortality and effectiveness of prophylaxis for Pneumocystis jiroveci pneumonia among rheumatic patients: a territory-wide study. Ann Clin Microbiol Antimicrob. 2021; 20 (1): 78. doi: 10.1186/s12941-021-00483-2.Chan S.C.W., Chung H.Y., Lau C.S., Li P.H. Epidemiology, mortality and effectiveness of prophylaxis for Pneumocystis jiroveci pneumonia among rheumatic patients: a territory-wide study. Ann Clin Microbiol Antimicrob. 2021; 20 (1): 78. doi: 10.1186/s12941-021-00483-2.Huang, L., Fu, Q., Ye, Y. et al. High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center. Arthritis Res Ther. 2021; 23 (1): 232. doi: 10.1186/s13075-021-02606-8.Huang, L., Fu, Q., Ye, Y. et al. High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center. Arthritis Res Ther. 2021; 23 (1): 232. doi: 10.1186/s13075-021-02606-8.Hsu H.C., Chang Y.S., Hou T.Y. et al. Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study. Clin Rheumatol. 2021; 40 (9): 3755–3763. doi: 10.1007/s10067-021-05660-4. Epub 2021 Mar 1.Hsu H.C., Chang Y.S., Hou T.Y. et al. Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study. Clin Rheumatol. 2021; 40 (9): 3755–3763. doi: 10.1007/s10067-021-05660-4. Epub 2021 Mar 1.Zhao Z., Huang Y., Ming B. et al. Characterization and associated risk factors of Pneumocystis jirovecii pneumonia in patients with AIRD: A retrospective study. Rheumatology (Oxford). 2022; 61 (9): 3766–3776. doi: 10.1093/rheumatology/keab941.Zhao Z., Huang Y., Ming B. et al. Characterization and associated risk factors of Pneumocystis jirovecii pneumonia in patients with AIRD: A retrospective study. Rheumatology (Oxford). 2022; 61 (9): 3766–3776. doi: 10.1093/rheumatology/keab941.Ishikawa Yu., Nakano K., Tokutsu K. et al. Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases. RMD Open. 2021; 7 (1): e001508. doi: 10.1136/rmdopen-2020-001508.Ishikawa Yu., Nakano K., Tokutsu K. et al. Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases. RMD Open. 2021; 7 (1): e001508. doi: 10.1136/rmdopen-2020-001508.Kageyama T., Furuta S., Ikeda K. et al. Prognostic factors of Pneumocystis pneumonia in patients with systemic autoimmune diseases. PLoS One. 2019; 14 (3): e0214324. doi: 10.1371/journal.pone.0214324. eCollection 2019.Kageyama T., Furuta S., Ikeda K. et al. Prognostic factors of Pneumocystis pneumonia in patients with systemic autoimmune diseases. PLoS One. 2019; 14 (3): e0214324. doi: 10.1371/journal.pone.0214324. eCollection 2019.Sonomoto K., Tanaka H., Nguyen T.M. et al. Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry. Rheumatology. 2022; 61 (5): 1831–1840. doi: 10.1093/rheumatology/keab647.Sonomoto K., Tanaka H., Nguyen T.M. et al. Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry. Rheumatology. 2022; 61 (5): 1831–1840. doi: 10.1093/rheumatology/keab647.Komano Y., Harigai M., Koike R. et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009; 61 (3): 305–312. doi: 10.1002/art.24283.Komano Y., Harigai M., Koike R. et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009; 61 (3): 305–312. doi: 10.1002/art.24283.US Food and Administration. Drug Safety update on TNF-alpha antagonists: infliximab and etanercept. https://wayback.archiveit.org/7993/20180127041103/ https://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety_revision2.htm. Accessed May 3, 2022.US Food and Administration. Drug Safety update on TNF-alpha antagonists: infliximab and etanercept. https://wayback.archiveit.org/7993/20180127041103/ https://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety_revision2.htm. Accessed May 3, 2022.Calero-Bernal M.L., Martin-Garrido I., Donazar-Ezcurra M. et al. Intermittent courses of corticosteroids also present a risk for pneumonia in non-HIV patients. Can Respir J 2016; 2016: 2464791. doi: 10.1155/2016/ 2464791. Epub 2016 Sep 18.Calero-Bernal M.L., Martin-Garrido I., Donazar-Ezcurra M. et al. Intermittent courses of corticosteroids also present a risk for pneumonia in non-HIV patients. Can Respir J 2016; 2016: 2464791. doi: 10.1155/2016/ 2464791. Epub 2016 Sep 18.Alexandre K., Ingen-Housz-Oro S., Versini M. et al. Pneumocystis jirovecii pneumonia in patients treated with rituximab for systemic diseases: report of 11 cases and review of the literature. Eur J Intern Med. 2018; 50: e23–e24. doi: 10.1016/j.ejim.2017.11.014.Alexandre K., Ingen-Housz-Oro S., Versini M. et al. Pneumocystis jirovecii pneumonia in patients treated with rituximab for systemic diseases: report of 11 cases and review of the literature. Eur J Intern Med. 2018; 50: e23–e24. doi: 10.1016/j.ejim.2017.11.014.Park J.W., Curtis J.R., Jun K.I. et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab. Chest. 2022 May; 161 (5): 1201–1210. doi: 10.1016/j.chest.2021.11.007. Epub 2021 Nov 14.Park J.W., Curtis J.R., Jun K.I. et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab. Chest. 2022 May; 161 (5): 1201–1210. doi: 10.1016/j.chest.2021.11.007. Epub 2021 Nov 14.Schmajuk G., Jafri K., Evans M. et al. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Semin Arthritis Rheum. 2019; 48 (6): 1087–1092. doi: 10.1016/j.semarthrit.2018.10.018. Epub 2018 Nov 3.Schmajuk G., Jafri K., Evans M. et al. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Semin Arthritis Rheum. 2019; 48 (6): 1087–1092. doi: 10.1016/j.semarthrit.2018.10.018. Epub 2018 Nov 3.Mori S., Cho I., Sugimoto M. A followup study of asymptomatic carriers of Pneumocystis jiroveci during Accepted Manuscript immunosuppressive therapy for rheumatoid arthritis. J Rheumatol. 2009; 36: 1600–1605. doi: 10.3899/jrheum.081270. Epub 2009 Jun 16.Mori S., Cho I., Sugimoto M. A followup study of asymptomatic carriers of Pneumocystis jiroveci during Accepted Manuscript immunosuppressive therapy for rheumatoid arthritis. J Rheumatol. 2009; 36: 1600–1605. doi: 10.3899/jrheum.081270. Epub 2009 Jun 16.Nossent J., Keen H., Preen D., Inderjeeth C. Hospitalisation for tuberculosis and other opportunistic infections in patients with inflammatory joint diseases before and after the introduction of biological therapy. Ann Rheum Dis. 2022; 81 (Suppl 1): 182Nossent J., Keen H., Preen D., Inderjeeth C. Hospitalisation for tuberculosis and other opportunistic infections in patients with inflammatory joint diseases before and after the introduction of biological therapy. Ann Rheum Dis. 2022; 81 (Suppl 1): 182Nossent J., Keen H., Preen D., Inderjeeth C. Temporal trend in hospitalisation for opportunistic infections in patients with connective tissue diseases. Ann Rheum Dis. 2022; 81 (Suppl 1): 661. https://doi.org/10.1136/annrheumdis-2022-eular.2552Nossent J., Keen H., Preen D., Inderjeeth C. Temporal trend in hospitalisation for opportunistic infections in patients with connective tissue diseases. Ann Rheum Dis. 2022; 81 (Suppl 1): 661. https://doi.org/10.1136/annrheumdis-2022-eular.2552Grigoropoulos I., Thomas K., Christoforou P. et al. Pneumocystis jirovecii pneumonia after initiation of tofacitinib therapy in rheumatoid arthritis: case-based review. Mediterr J Rheumatol. 2019; 30 (3): 167–170. doi: 10.31138/mjr.30.3.167. eCollection 2019 Sep.Grigoropoulos I., Thomas K., Christoforou P. et al. Pneumocystis jirovecii pneumonia after initiation of tofacitinib therapy in rheumatoid arthritis: case-based review. Mediterr J Rheumatol. 2019; 30 (3): 167–170. doi: 10.31138/mjr.30.3.167. eCollection 2019 Sep.Lourenço J., Carreira P. Non-lymphopenic pneumocystis pneumonia in low-dose methotrexate therapy: An exception to every rule. Respir Med Case Rep. 2020; 31: 101289. doi: 10.1016/j.rmcr.2020.101289. eCollection 2020.Lourenço J., Carreira P. Non-lymphopenic pneumocystis pneumonia in low-dose methotrexate therapy: An exception to every rule. Respir Med Case Rep. 2020; 31: 101289. doi: 10.1016/j.rmcr.2020.101289. eCollection 2020.Ohmura S.I., Homma Y., Masui T., Miyamoto T. Factors associated with pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving methotrexate: a single-center retrospective study. Intern Med. 2022; 61 (7): 997–1006. doi: 10.2169/internalmedicine.8205-21. Epub 2021 Sep 11.Ohmura S.I., Homma Y., Masui T., Miyamoto T. Factors associated with pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving methotrexate: a single-center retrospective study. Intern Med. 2022; 61 (7): 997–1006. doi: 10.2169/internalmedicine.8205-21. Epub 2021 Sep 11.Nunokawa T., Yokogawa N., Shimada K., Sugii S. Effect of sulfasalazine use on the presence of Pneumocystis organisms in the lung among patients with rheumatoid arthritis: A test-negative design case-control study with PCR tests. Mod Rheumatol. 2019; 29 (3): 436–440. doi: 10.1080/14397595.2018.1465647. Epub 2018 May 3.Nunokawa T., Yokogawa N., Shimada K., Sugii S. Effect of sulfasalazine use on the presence of Pneumocystis organisms in the lung among patients with rheumatoid arthritis: A test-negative design case-control study with PCR tests. Mod Rheumatol. 2019; 29 (3): 436–440. doi: 10.1080/14397595.2018.1465647. Epub 2018 May 3.Honda N., Tagashira Y., Kawai S. et al. Reduction of Pneumocystis jirovecii pneumonia and bloodstream infections by trimethoprim-sulfamethoxazole prophylaxis in patients with rheumatic diseases. Scand J Rheumatol. 2021; 50 (5): 365–371. doi: 10.1080/03009742.2020.1850854. Epub 2021 Mar 22.Honda N., Tagashira Y., Kawai S. et al. Reduction of Pneumocystis jirovecii pneumonia and bloodstream infections by trimethoprim-sulfamethoxazole prophylaxis in patients with rheumatic diseases. Scand J Rheumatol. 2021; 50 (5): 365–371. doi: 10.1080/03009742.2020.1850854. Epub 2021 Mar 22.Kimura M., Tanaka S., Ishikawa A. et al. Comparison of trimethoprimsulfamethoxazole and aerosolized pentamidine for primary prophylaxis of pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease. Rheumatol Int. 2008; 28 (7): 673–676. doi: 10.1007/s00296-007-0505-4.Kimura M., Tanaka S., Ishikawa A. et al. Comparison of trimethoprimsulfamethoxazole and aerosolized pentamidine for primary prophylaxis of pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease. Rheumatol Int. 2008; 28 (7): 673–676. doi: 10.1007/s00296-007-0505-4.Kitazawa T., Seo K., Yoshino Y. et al. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of pneumocystis jirovecii pneumonia in patients with connective tissue diseases. J Infect Chemother. 2019; 25 (5): 351–354. doi: 10.1016/j.jiac.2019.01.005. Epub 2019 Jan 31.Kitazawa T., Seo K., Yoshino Y. et al. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of pneumocystis jirovecii pneumonia in patients with connective tissue diseases. J Infect Chemother. 2019; 25 (5): 351–354. doi: 10.1016/j.jiac.2019.01.005. Epub 2019 Jan 31.Freeman C.D., Klutman N.E., Lamp K.C. et al. Relative Bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother. 1998; 32 (10): 1004–1007. doi: 10.1345/aph.17464.Freeman C.D., Klutman N.E., Lamp K.C. et al. Relative Bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother. 1998; 32 (10): 1004–1007. doi: 10.1345/aph.17464.Jinno S., Akashi K., Onishi A., Nose Y., Yamashita M., Saegusa J. Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids. Rheumatol Int. 2022 Aug; 42 (8): 1403–1409. doi: 10.1007/s00296-021-04945-w.Jinno S., Akashi K., Onishi A., Nose Y., Yamashita M., Saegusa J. Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids. Rheumatol Int. 2022 Aug; 42 (8): 1403–1409. doi: 10.1007/s00296-021-04945-w.Hiramoto K., Akiyama M., Kaneko Y. Risk factors for adverse events of sulfamethoxazole-trimethoprim prophylaxis in patients with systemic rheumatic diseases. Ann Rheum Dis. 2022; 81 (Suppl 1): 1055. https://doi.org/10.1136/annrheumdis-2022-eular.2215Hiramoto K., Akiyama M., Kaneko Y. Risk factors for adverse events of sulfamethoxazole-trimethoprim prophylaxis in patients with systemic rheumatic diseases. Ann Rheum Dis. 2022; 81 (Suppl 1): 1055. https://doi.org/10.1136/annrheumdis-2022-eular.2215Utsunomiya M., Dobashi H., Odani T. et al. An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up. Rheumatol Adv Pract. 2020; 4 (2): rkaa029. doi: 10.1093/rap/rkaa029. eCollection 2020.Utsunomiya M., Dobashi H., Odani T. et al. An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up. Rheumatol Adv Pract. 2020; 4 (2): rkaa029. doi: 10.1093/rap/rkaa029. eCollection 2020.Harada T., Kato R., Sueda Y. et al. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with rheumatic diseases. Mod Rheumatol. 2021; 31 (3): 629–635. doi: 10.1080/14397595.2020.1812834. Epub 2020 Sep 9.Harada T., Kato R., Sueda Y. et al. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with rheumatic diseases. Mod Rheumatol. 2021; 31 (3): 629–635. doi: 10.1080/14397595.2020.1812834. Epub 2020 Sep 9.Goyal N., Chung M., Bernheim A. et al. Computed tomography features of coronavirus disease 2019 (COVID-19): a review for radiologists. J Thorac Imaging. 2020; 35 (4): 211–218. oi: 10.1097/RTI.0000000000000527.Goyal N., Chung M., Bernheim A. et al. Computed tomography features of coronavirus disease 2019 (COVID-19): a review for radiologists. J Thorac Imaging. 2020; 35 (4): 211–218. oi: 10.1097/RTI.0000000000000527.Hochhegger B., Zanon M., Altmayer S. et al. COVID-19 mimics on chest CT: a pictorial review and radiologic guide. Br J Radiol. 2021; 94 (1118): 20200703. doi: 10.1259/bjr.20200703. Epub 2020 Dec 9.Hochhegger B., Zanon M., Altmayer S. et al. COVID-19 mimics on chest CT: a pictorial review and radiologic guide. Br J Radiol. 2021; 94 (1118): 20200703. doi: 10.1259/bjr.20200703. Epub 2020 Dec 9.Bhatt K., Agolli A., Patel M.H. et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries (Craiova). 2021; 9 (1): e126. doi: 10.15190/d.2021.5.Bhatt K., Agolli A., Patel M.H. et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries (Craiova). 2021; 9 (1): e126. doi: 10.15190/d.2021.5.Menon A.A., Berg D.D., Brea E.J. et al. A Case of COVID-19 and Pneumocystis jirovecii Coinfection. Am J Respir Crit Care Med. 2020; 202 (1): 136–138. doi: 10.1164/rccm.202003-0766LE.Menon A.A., Berg D.D., Brea E.J. et al. A Case of COVID-19 and Pneumocystis jirovecii Coinfection. Am J Respir Crit Care Med. 2020; 202 (1): 136–138. doi: 10.1164/rccm.202003-0766LE.Gentile I., Viceconte G., Lanzardo A. et al. Pneumocystis jirovecii pneumonia in non-HIV patients recovering from COVID-19: a single-center experience. Int J Environ Res Public Health. 2021; 18 (21): 11399. doi: 10.3390/ijerph182111399.Gentile I., Viceconte G., Lanzardo A. et al. Pneumocystis jirovecii pneumonia in non-HIV patients recovering from COVID-19: a single-center experience. Int J Environ Res Public Health. 2021; 18 (21): 11399. doi: 10.3390/ijerph182111399.

The authors declare that there are no conflicts of interest present.